Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

9 treatments under study, led by Begrivac

Research Leaders

5 sponsors active, led by Chiltern Pesquisa Clinica Ltda

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 7 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

6Total
Phase 2 (3)
Phase 3 (3)

Trial Status

Completed6
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 6 completed trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00992017Phase 2Completed

Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women

NCT00992836Phase 2Completed

Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth

NCT01032395Phase 3CompletedPrimary

Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus

NCT01032408Phase 3CompletedPrimary

Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection

NCT01031719Phase 3CompletedPrimary

Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors

NCT00978120Phase 2CompletedPrimary

Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma

NCT01277380UnknownPrimary

Analysis of the Results From Influenza Rapid Test A Positive and H1N1 Real Time RT-PCR

Showing all 7 trials

Research Network

Common Treatments

  • Begrivac2
  • Focetria2
  • Fluad1
  • H1n1 Vaccine Low Dose1
  • Influenza A H1n1 2009 Monovalent Vaccine1

Active Sponsors

  • Chiltern Pesquisa Clinica Ltda3
  • National Institute of Allergy and Infectious Diseases (NIAID)3
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2
  • Taipei Medical University WanFang Hospital1
  • National Heart, Lung, and Blood Institute (NHLBI)1

Top Investigators

Related Conditions

  • Hiv Infections2
  • Diabetes Mellitus1
  • Chronic Pulmonary Disease1
  • Chronic Heart Disease1
  • Human Immunodeficiency Virus Type 1 Hiv1 Infection1

Activity Timeline